Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma

Experimental Hematology & Oncology

José E Guimarães¹  Fernanda Trigo¹  Rui Bergantim¹ 

[1] Faculty of Medicine, University of Porto, Porto, Portugal

关键词: Tandem transplant;    Autologous stem cell transplant;    Bone marrow transplantation;    Multiple myeloma;   

Others  :  814586
DOI  :  10.1186/2162-3619-1-35

 received in 2012-10-12, accepted in 2012-11-21,  发布年份 2012

【 摘 要 】

Background

Multiple Myeloma (MM) is the commonest indication for autologous stem cell transplantation (ASCT).

Methods

We retrospectively analysed data from 85 patients with MM submitted to ASCT in our centre from 2000 to 2010: 132 ASCT were realized, 80 of them as tandem.

Results

After induction, 17.6% were in complete remission (CR), 41.2% in very good partial remission (VGPR) and 41.2% in partial remission (PR). After transplant 44.7% were in CR, 15.3% in VGPR and 40% in PR. With 22 months (range – 3 to 117 months) of median follow-up, median overall survival (OS) was 43 months and progression-free survival (PFS) 22 months. At 5 years, OS was 45.3% (36.7-53.9%, 95%) and PFS 24.5% (18-31%, 95%). Patients with CR after ASCT had significantly longer PFS as compared to patients with PR (27 vs 7 months; p = 0.034) but not when compared to patients with VGPR (27 vs 19 months, p = 0.485). The tandem approach represented an advantage in OS and PFS when compared to only one ASCT (31 vs 19 months - p = 0.018, and 40 vs 31 - p = 0.04, respectively).

Conclusions

Our results highlight the impact of response to transplant in patients PFS and tandem modality showed to carry better PFS and OS then the single transplant.

【 授权许可】

   
2012 Bergantim et al.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Palumbo A, Anderson K: Multiple myeloma. N Eng J Med 2011, 364(11):1046-1060.
• [2]Kyle R, Rajkumar SV: Multiple myeloma. Blood 2008, 111(6):2962-2972.
• [3]Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M: Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007, 25(15):1993-1999.
• [4]Durie BG, Salmon SE: The clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975, 36(3):842-854.
• [5]Greipp PR, San Miguel J, Durie BGM, et al.: INTERNATIONAL al staging system for multiple myeloma. J Clin Oncol 2005, 23(15):3412-3420.
• [6]Hervé AL, Florence M, Philippe M, et al.: Molecular heterogeneity of multiple myeloma: pathogenesis is, prognosis, and therapeutic Implications. J Clin Oncol 2011, 29(14):1893-1897.
• [7]Kyle RA: a. Multiple myeloma. N Eng J Med 2004, 351(18):1860-1873.
• [8]CS Ma, Davies FE, Laubach JP, et al.: Future directions of next-generation novel Therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 2011, 29(14):1916-1923.
• [9]Barlogie B, Attal M, Crowley J, et al.: Long-term follow-up trials of autotransplantation for multiple myeloma: update of the intergroup protocols Conducted by francophone du myeloma, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol 2010, 28(7):1209-1214.
• [10]Gertz Ma, Ansell SM, Dingli D, et al.: Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative. Mayo Clin Proc 2008, 83(10):1131-1135.
• [11]Harousseau JL, Moreau P: Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Eng J Med 2009, 360(25):2645-2654.
• [12]Attal M, Harousseau JL, Stoppa M, et al.: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroup Français du Myeloma. N Eng J Med 1996, 335(2):91-97.
• [13]Hussein M: Role of high-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. J Clin Oncol 2004, 18(4):893.
• [14]Cavo M, Rajkumar SV, Palumbo A, et al.: International Myeloma Working Group (IMWG) consensus approach to the Treatment of Multiple Myeloma Patients who are candidates for autologous stem-cell transplantation. Blood 2011, 117(23):6063-6073.
• [15]Engelhardt M, Udi J, Kleber M, et al.: European Myeloma Network: The 3rd Trialist Forum Consensus Statement from the European expert meeting on multiple myeloma. Leuk Lymphoma 2010, 51(11):2006-2011.
• [16]Palumbo A, Facon T, Sonneveld P, et al.: Thalidomide for Treatment of multiple myeloma: 10 years later. Blood 2008, 111(8):3968-3977.
• [17]San Miguel JF, Schlag R, Khuageva NK, et al.: Bortezomib plus melphalan and prednisone for initial Treatment of multiple myeloma. N Eng J Med 2008, 359(9):906-917.
• [18]Jagannath S, Durie BGM, Wolf J, et al.: Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005, 129(6):776-783.
• [19]Harousseau JL, Attal M, Stoppa A-m, Renaud M, Huriez CH: Bortezomib plus dexamethasone the induction Treatment prior to autologous stem cell transplantation in Patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006, 91:1498-1505.
• [20]Dimopoulos M, Spencer A, Attal M, et al.: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Eng J Med 2007, 357(21):2123-2132.
• [21]Palumbo A, Dimopoulos M, San Miguel J, et al.: Lenalidomide in combination with dexamethasone for the Treatment of relapsed or refractory multiple myeloma. Blood Rev 2009, 23(2):87-93.
• [22]Kumar SK, Rajkumar SV, Dispenzieri A, et al.: Improved survival in multiple myeloma and the Impact of Novel Therapies. Blood 2008, 111(5):2516-2520.
• [23]Laubach JP, Mitsiades CS, the Mahindra, et al.: The use of novel agents in the Treatment of relapsed and refractory multiple myeloma. Leukemia 2009, 23(12):2222-2232.
• [24]Dingli D, Rajkumar SV: How best to use new Therapies in multiple myeloma. Blood Rev 2010, 24(3):91-100.
• [25]Oken MM, Creech RH, Tormey DC, et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5(6):649-655.
• [26]Goldschmidt H, Hegenbart U, Haas R, Hunstein W: Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in Patients with multiple myeloma. Bone Marrow Transplant 1996, 17(5):691-697.
• [27]Gertz M, Kumar S, Lacy MQ, et al.: Comparison of high-dose CY with growth factor and growth factor alone for mobilization of stem cells for transplantation in Patients with multiple myeloma. Bone Marrow Transplant 2010, 43(8):619-625.
• [28]Moreau P: Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan conditioning regimens for the peripheral blood stem cell transplantation in Patients with newly diagnosed multiple myeloma: final analysis of the Intergroup Francop. Blood 2002, 99(3):731-735.
• [29]Durie BGM, Harousseau JL, Miguel JS, et al.: International uniform response criteria for multiple myeloma. Leukemia 2006, 20(9):1467-1473.
• [30]Services of UD HAH: Terminology Common Criteria for Adverse Events (CTCAE).2010; 2009. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/About.html webcite
• [31]Moreau P, Hullin C, Garban F, et al.: Tandem autologous stem cell transplantation in high-risk new multiple myeloma: final results of the prospective and randomized IFM 99–04 protocol. Blood 2006, 107(1):397-403.
• [32]Harousseau JL, Attal M, Avet-Loiseau H: The role of complete response in multiple myeloma. Blood 2009, 114(15):3139-3146.
• [33]Van de Velde HJK, Liu X, Chen G, et al.: Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007, 92(10):1399-1406.
• [34]Lahuerta JJ, Mateos MV, Martínez-López J, et al.: Influence of pre-and post-transplantation outcome of responses on Patients with multiple myeloma: response of sequential improvement and achievement of complete response are Associated with longer survival. J Clin Oncol 2008, 26(35):5775-5782.
• [35]Chanan-Khan AA, Giralt S: Importance of Achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010, 28(15):2612-2624.
• [36]Martinez-Lopez J, Blade J, Mateos MV, et al.: Long-term Prognostic Significance of response in multiple myeloma after stem cell transplantation. Blood 2011, 118:529-534.
• [37]Rajkumar SV, Gahrton G, Bergsagel PL: Approach to the Treatment of multiple myeloma: a clash of philosophies. Blood 2011, 118(12):3205-3211.
• [38]Haessler J, Shaughnessy JD, Zhan F, et al.: Benefit of complete response in multiple myeloma limited to high-risk Subgroup Identified by gene expression profiling. Clin Cancer Res 2007, 13(23):7073-7079.
• [39]Gertz MA, Gastineau DA, Lacy MQ, et al.: Without SCT in multiple myeloma growth factor: engraftment kinetics, hospitalization and bacteremia. Bone Marrow Transplant 2011, 46(7):956-961.
• [40]Barlogie B, Jagannath S, Desikan KR, et al.: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999, 93(1):55-65.
• [41]Cavo M, Tosi P, Zamagni E, et al.: Prospective, randomized study of single Compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007, 25(17):2434-2441.
• [42]Sonneveld P, van der Holt B, Segeren CM, et al.: Intermediate-dose melphalan myeloablative Compared with Treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group trial HOVON 24. Haematologica 2007, 92(7):928-935.
• [43]Attal M, Harousseau JL, Facon T, et al.: Single versus double autologous stem-cell transplantation for multiple myeloma. N Eng J Med 2003, 349(26):2495-2502.
• [44]Moreau P, Avet-Loiseau H, Harousseau JL, Attal M: Current trends in autologous stem-cell transplantation for myeloma in the era of Novel Therapies. J Clin Oncol 2011, 29(14):1898-1906.
• [45]Rajkumar SV: Treatment of myeloma: cure vs control. Mayo Clin Proc 2008, 83(10):1142-1145.
• [46]Kroger N, Badbaran A, Zabelina T, et al.: Impact of high risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2012,  . [Epub ahead of print]
• [47]Bjorkstrand B, Iacobelli S, Hegenbart U, et al.: Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011, 29(22):3016-3022.
• [48]Armenson KE, Hill EG, Costa LJ: Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 2012,  . Epub ahead of print
• [49]Krishnan A, Pasquini MC, Logan B, et al.: Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011, 12(13):1195-1203.
• [50]Richardson PG, Weller E, Lonial S, et al.: Lenalidomide, bortezomib, and dexamethasone combination therapy in Patients with newly diagnosed multiple myeloma. Blood 2010, 116(5):679-686.
• [51]Jakubowiak AJ, Griffith K, Reece DE, et al.: Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1 / 2 Multiple Myeloma Research Consortium trial. Blood 2011, 118(3):535-543.
• [52]Kumar S, Flinn IW, Noga S, Rifkin R, Rajkumar S: Bortezomib, dexamethasone, and cyclophosphamide combination lenalidomide for newly diagnosed multiple myeloma: phase 1 results from the multicenter study EVOLUTION. Leukemia 2011, 24(7):1350-1356.
• [53]MFI / DFCI. TRIAL DFCI003 / 10–050: A Randomized Phase III Study Comparing Conventional Dose Combination of Treatment Using The lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma. Available at: http://www.ifm-dfci.org/ webcite